Skip to main content

Clinical trial origAMI-2

A Randomized, Open-label Phase 3 Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer

Cancers
Organ Colon
Trial status Trial open for recruitment
Investigator
Trial type
Interventional with experimental drug
Phase Trial phase 3
Academic trial Non
Sponsor Janssen Cilag
EudraCT Identifier 2024-513852-13-00
ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT06662786
Last update